Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data

Background and Objective: Radium-223 dichloride (Xofigo(®)) is a calcium mimetic agent approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. This targeted, α-particle-emitting therapy has demonstrated si...

Descripción completa

Detalles Bibliográficos
Autores principales: Soldatos, Theodoros G., Iakovou, Ioannis, Sachpekidis, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572036/
https://www.ncbi.nlm.nih.gov/pubmed/31100964
http://dx.doi.org/10.3390/medicina55050149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572036/
https://www.ncbi.nlm.nih.gov/pubmed/31100964
http://dx.doi.org/10.3390/medicina55050149

Ejemplares similares